プリマ・バイオメッド【IMMP】の掲示板

>>4

公開情報からの引用、抜粋

↓

Immutep's Q3 FY25 update demonstrates significant advancement in their clinical development pipeline, most notably with the first patient dosed in their pivotal TACTI-004 Phase III trial. This represents a critical milestone that substantially derisks their development path for eftilagimod alfa (efti) in non-small cell lung cancer, one of oncology's largest market opportunities as explicitly noted in the report.

The Phase III trial's scope is substantial, involving 756 patients across more than 150 clinical sites with regulatory approvals expanded to 19 countries. This global footprint accelerates enrollment potential and broadens future commercial possibilities if successful.

↓
よし
集めていくか